{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:16:35Z","timestamp":1780992995212,"version":"3.54.1"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To compare real\u2010world antidiabetic treatment outcomes over 12 months in obese people with type 2 diabetes mellitus (T2DM) who previously received oral antidiabetic therapy and then initiated a first injectable therapy with liraglutide or basal insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      This was a retrospective, propensity score\u2010matched, longitudinal cohort study using real\u2010world data (January 2010 to December 2015) from the Dutch PHARMO Database Network. Adult obese (body mass index [BMI] \u226535 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) patients with T2DM with \u22652 dispensing dates for liraglutide or basal insulin supported oral therapy (BOT) were selected. The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline during 12 months of follow\u2010up. The secondary endpoints were the changes in weight, BMI and cardiovascular risk factors from baseline. Clinical data were analysed using descriptive statistics and compared using mixed models for repeated measures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Obese patients with T2DM (\n                      <jats:italic>N<\/jats:italic>\n                      = 1157) in each treatment group were matched (liraglutide cohort,\n                      <jats:italic>n<\/jats:italic>\n                      = 544; BOT cohort,\n                      <jats:italic>n<\/jats:italic>\n                      = 613). From 3 months onwards, glycaemic control improved in both cohorts but improved significantly more with liraglutide than with BOT (12 months: \u221212.2 mmol\/mol vs \u22128.8 mmol\/mol;\n                      <jats:italic>P<\/jats:italic>\n                      = .0053). In addition, weight and BMI were significantly lower for treatments with liraglutide vs BOT (12 months: \u22126.0 kg vs \u22121.6 kg and \u2212 2.1 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      vs \u22120.5 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , respectively;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .0001 for both). No significant differences were seen in changes in cardiovascular risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this real\u2010world study in matched obese patients with T2DM showed that liraglutide was more effective than BOT for HbA1c control and weight\/BMI reductions. Patients were more likely to maintain glycaemic control over time after initiating liraglutide than after initiating BOT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13335","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T01:13:52Z","timestamp":1525396432000},"page":"2093-2102","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical effectiveness of liraglutide vs basal insulin in a real\u2010world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0935-5193","authenticated-orcid":false,"given":"Jetty A.","family":"Overbeek","sequence":"first","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research  Utrecht the Netherlands"},{"name":"Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute VU University Medical Centre Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M.","family":"Heintjes","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline L.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Novo Nordisk Farma BV, Alphen aan den Rijn  the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Tikkanen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Region Europe Pharmaceuticals AS  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnout W.","family":"van Diermen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Farma BV, Alphen aan den Rijn  the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernie J.A.","family":"Penning\u2010van Beest","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron M.C.","family":"Herings","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research  Utrecht the Netherlands"},{"name":"Department of Epidemiology and Biostatistics VU University Medical Center Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.11.007"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000368191.86614.5a"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1190-x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9973-5"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-014-1479-4"},{"issue":"7","key":"e_1_2_6_7_1","first-page":"1033","article-title":"Economic costs of diabetes in the U.S. in 2012","volume":"39","author":"Petersen M","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/13102818.2015.1042912"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medici.2014.05.007"},{"issue":"7","key":"e_1_2_6_10_1","first-page":"281","article-title":"The current total economic burden of diabetes mellitus in the Netherlands","volume":"75","author":"Peters ML","year":"2017","journal-title":"Neth J Med"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2534-0"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0"},{"key":"e_1_2_6_13_1","article-title":"A clinical perspective of obesity, metabolic syndrome and cardiovascular disease","volume":"5","author":"Han TS","year":"2016","journal-title":"JRSM Cardiovasc Dis"},{"issue":"3","key":"e_1_2_6_14_1","first-page":"753","article-title":"Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors","volume":"9","author":"Yandrapalli S","year":"2015","journal-title":"Diabetes Care"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.09.003"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01123.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12287"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12804"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2017.08.001"},{"key":"e_1_2_6_20_1","unstructured":"PHARMO Institute for Drug Outcomes Research.www.pharmo.nl. 2015. Accessed November 16 2017."},{"key":"e_1_2_6_21_1","first-page":"512","article-title":"NHG\u2010standaard diabetes mellitus type 2 (Derde herziening)","volume":"56","author":"Rutten GEHM","year":"2013","journal-title":"Huisarts Wet"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/80.2.257"},{"issue":"43","key":"e_1_2_6_23_1","article-title":"Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data","volume":"16","author":"Ashbeck EL","year":"2016","journal-title":"BMC Med Res Methodol."},{"key":"e_1_2_6_24_1","first-page":"107","article-title":"Comparative effectiveness of liraglutide in the treatment of type 2 diabetes","volume":"7","author":"Rigato M","year":"2014","journal-title":"Diabetes, Metab Syndr Obes Targets Ther"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0180-0"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0074-8"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814559725"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.01.009"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","unstructured":"SvenssonE BaggesenLM JohnsenSP et al.Early glycemic control and magnitude of HbA1c reduction predict cardiovascular events and mortality: population\u2010based cohort study of 24 752 metformin initiators.Diabetes Care.2017;40:800\u2010807.https:\/\/doi.org\/10.2337\/dc16-2271.","DOI":"10.2337\/dc16-2271"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-309164"},{"key":"e_1_2_6_32_1","first-page":"1443","article-title":"Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment","volume":"9","author":"Morillas C","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0199-z"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:48:27Z","timestamp":1761889707000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/dom.13335"],"URL":"https:\/\/doi.org\/10.1111\/dom.13335","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"2018-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}